Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563117 | 0.91 | MET (1.00) | METKDRPDGFRAKIT | |
| SCHEMBL12376541 | 0.85 | MET (1.00) | METKDRPDGFRAKIT | |
| SCHEMBL3564746 | 0.81 | MET (0.70) | METKDRPDGFRAKITBRAF | |
| SCHEMBL3561466 | 0.81 | MET (0.69) | METKDRPDGFRAKIT | |
| SCHEMBL5093594 | 0.81 | MET (0.69) | METKDRPDGFRAKITBRAF | |
| SCHEMBL3564743 | 0.79 | MET (0.75) | METKDRPDGFRAKIT | |
| SCHEMBL6505753 | 0.79 | MET (0.85) | METKDRPDGFRAKIT | |
| SCHEMBL3561459 | 0.79 | MET (0.74) | METKDRPDGFRAKIT | |
| SCHEMBL1877226 | 0.78 | PDGFRA (0.84) | METKDRPDGFRAKIT | |
| SCHEMBL2282742 | 0.78 | MET (1.00) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885KDR 419/4885PDGFRA 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.